This episode will outline each barrier discussed in podcast #1 and then offer resources and solutions

This episode will review the current evidence of underdiagnosis of PIDD in minority/underserved populations.

For today’s episode we will be reviewing articles from the January-February 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics.

Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.

Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today’s episode we will be reviewing articles from the November-December 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype.

Novel airway smooth muscle-mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma.

Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today’s episode we will be reviewing articles from the November-December 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. 

Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis.

Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging discussion with the opportunity for ongoing conversation about today's topic!

Article links:

Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. 

Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Changes in asthma severity in the first year of school and difficulty learning to read.

IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Reintroduction failure after negative food challenges in adults is common and mainly due to atypical symptoms.

Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy.

Home self-monitoring in patients with asthma using a mobile spirometry system.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Show notes for Episode 16:

For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis.

Trends and Disparities in Asthma Biologic Use in the United States.

Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today’s episode we will be reviewing three more articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article links:

Prenatal and Early-Life Exposure to Indoor Air-Polluting Factors and Allergic Sensitization at 2 Years of Age

Impact of Sinus Surgery on Type 2 Airway and Systemic Inflammation in Asthma

Long-term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.